Invasive aspergillosis in patients with liver disease

Medical Mycology

Volumn 49, Issue 4, 2011, Pages 406-413

  Falcone, Marco ^a   Massetti, Anna Paola ^a   Russo, Alessandro ^a   Vullo, Vincenzo ^a   Venditti, Mario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

A spergillus species; antifungal therapy; galactomannan; invasive aspergillosis; liver diseases

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUTICASONE; GALACTOMANNAN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METHYLPREDNISOLONE; MICAFUNGIN; VANCOMYCIN; VORICONAZOLE;

ACUTE LIVER FAILURE; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; INVASIVE ASPERGILLOSIS; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY;

AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ECHINOCANDINS; FATAL OUTCOME; HUMANS; LIVER DISEASES; LUNG; MALE; MIDDLE AGED; PYRIMIDINES; RISK FACTORS; TRIAZOLES;

ASPERGILLUS;

EID: 79955040220     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.535030     Document Type: Article

References (50)

1. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173: 707-717.
2. Roosen J, Frans E, Wilmer A, et al. Comparison of premortem clini-cal diagnoses in critically ill patients and subsequent autopsy f ndings. Mayo Clin Proc 2000; 75: 562-567. (Pubitemid 30395917)
3. Dimopoulos G, Piagnerelli M, Berre J, et al. Post mortem examination in the intensive care unit: still useful? Intensive Care Med 2004; 30: 2080-2085. (Pubitemid 40022325)
4. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205-216. (Pubitemid 47044802)
5. Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemio-logical, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577-584. (Pubitemid 44267116)
6. Panasiuk A, Wysocka J, Maciorkowska E. Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. World J Gastroenterol. 2005; 11: 7661-7665. (Pubitemid 43168433)
7. Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol 2007; 41: 403-411. (Pubitemid 46573071)
8. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised def nitions of inva-sive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
9. Enberg R, Bletzinger R, Burry VF. Disseminated aspergillosis during treatment of hepatic failure. J Pediatr 1973; 82: 737.
10. Blum J, Reed JC, Pizzo SV, Thompson WM. Miliary aspergillosis as-sociated with alcoholism. AJR Am J Roentgenol 1978; 131: 707-709.
11. Walsh TJ, Hutchins GM. Aspergillus mural endocarditis. Am J Clin Pathol 1979; 71: 640-644. (Pubitemid 9198614)
12. Brown E, Freedman S, Arbeit R, Come S. Invasive pulmonary asper-gillosis in an apparently nonimmunocompromised host. Am J Med 1980; 69: 624-627. (Pubitemid 10018721)
13. Smith GW, Walker DH. Disseminated infection with Aspergillus f avus in an alcoholic patient. South Med J 1982; 75: 1148-1150.
14. Park GR, Drummond GB, Lamb D, et al. Disseminated aspergillo-sis occurring in patients with respiratory, renal, and hepatic failure. Lancet 1982; 2: 179-183. (Pubitemid 12080518)
15. Walsh TJ, Hamilton SR. Disseminated aspergillosis complicating he-patic failure. Arch Intern Med 1983; 143: 1189-1191. (Pubitemid 13100654)
16. Sesma P, Alvarez JC, Llinares P, Suarez MD. Disseminated asper-gillosis complicating hepatic failure. Arch Intern Med 1984; 144: 861-862.
17. Ascah KJ, Hyland RH, Hutcheon MA, et al. Invasive aspergillosis in a 'healthy' patient. Can Med Assoc J 1984; 131: 332-335. (Pubitemid 14067908)
18. Wagner DK, Varkey B, Sheth NK, DaMert GJ. Epidural abscess, vertebral destruction, and paraplegia caused by extending infection from an aspergilloma. Am J Med 1985; 78: 518-522. (Pubitemid 15107939)
19. Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central ner-vous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology 1985; 35:1654-1657. (Pubitemid 16248681)
20. Karam GH, Griffn FM Jr. Invasive pulmonary aspergillosis in non-immunocompromised, nonneutropenic hosts. Rev Infect Dis 1986; 8: 357-363.
21. Watanabe A, Fujiwara M, Nagashima H. Aspergillosis in acute hepatic failure. J Med 1987; 18: 17-22. (Pubitemid 17108919)
22. Brems JJ, Hiatt JR, Klein AS, et al. Disseminated aspergillosis complicating orthotopic liver transplantation for fulminant hepatic failure refractory to corticosteroid therapy. Transplantation 1988; 46: 479-481.
23. Rolando N, Harvey F, Brahm J, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol 1991; 12: 1-9.
24. Kreisel W Therapy of invasive aspergillosis with itraconazole: our own experiences and review of the literature. Mycoses 1994; 37: 42-51.
25. Lim HL, Lau GK, Davis GL, et al. Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology 1994; 106: 248-251.
26. Kawamura S, Maesaki S, Omagari K, et al. Invasive pulmonary asper-gillosis diagnosed early by polymerase chain reaction assay. Intern Med 1999; 38: 744-746.
27. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol 2002; 33: 116-124.
28. Bond R, Walter A, Trigg ME. Severe aplastic anemia associated with hep-atitis and complicated by pulmonary aspergillosis: response to immune suppression and antifungal therapy. Del Med J 2002; 74: 339-343.
29. Dimopoulos G, Piagnerelli M, Berré J, et al. Disseminated aspergil-losis in intensive care unit patients: an autopsy study. J Chemother 2003; 15: 71-75. (Pubitemid 36349895)
30. Vandewoude K, Blot S, Benoit D, et al. Invasive aspergillosis in criti-cally ill patients: analysis of risk factors for acquisition and mortality. Acta Clin Belg 2004; 59: 251-257. (Pubitemid 40029482)
31. Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergil-losis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-625. (Pubitemid 39202203)
32. Scott JX, Kumar TS, Sanghi S, et al. Pulmonary aspergillosis in a child with hepatic failure. Indian J Gastroenterol 2004; 23: 147-148. (Pubitemid 39145728)
33. Alderson JW, Van Dinter TG Jr, Opatowsky MJ, Burton EC Dissemi-nated aspergillosis following inf iximab therapy in an immunosup-pressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. Med Gen Med 2005; 7: 7.
34. Lipke AB, Mihas AA. Non-decompensated cirrhosis as a risk factor for invasive aspergillosis: a case report and review of the immune dys-function of cirrhosis. Am J Med Sci 2007; 334: 314-316. (Pubitemid 351339294)
35. Prodanovic H, Cracco C, Massard J, et al. Invasive pulmonary asper-gillosis in patients with decompensated cirrhosis: case series. BMC Gastroenterol 2007; 7: 2.
36. Li D, Chen L, Ding X, et al. Hospital-acquired invasive pulmonary aspergillosis in patients with hepatic failure. BMC Gastroenterol 2008; 8: 32.
37. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bron-choalveolar lavage f uid: a tool for diagnosing aspergillosis in inten-sive care unit patients. Am J Respir Crit Care Med 2008; 177: 27-34.
38. Kaiser P, Thurnheer R, Moll C, et al. Invasive aspergillosis in non-neutropenic patients. Eur J Intern Med 2009; 20: 131-133.
39. Sykia A, Gigi E, Sinakos E, et al. Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive asper-gillosis in a patient with chronic hepatitis C during treatment with peg-interferon-a and ribavirin. J Gastrointestin Liver Dis 2009; 18: 118-119.
40. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30: 782-800. (Pubitemid 351194841)
41. Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000; 182: 526-533. (Pubitemid 30651050)
42. Lombardo L, Capaldi A, Poccardi G, Vineis P. Peripheral blood CD3 and CD4 T-lymphocyte reduction correlates with severity of liver cirrhosis. Int J Clin Lab Res 1995; 25: 153-156.
43. Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inf ammation for corticosteroid treatment and che-motherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494-503. (Pubitemid 40041144)
44. Kwak EJ, Husain S, Obman A, et al. Effcacy of galactomannan anti-gen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42: 435-438. (Pubitemid 38082765)
45. Kimura SI, Odawara J, Aoki T, et al. Detection of sputum Aspergillus galactomannan for diagnosis of invasive pulmonary aspergillosis in haematological patients. Int J Hematol 2009; 90: 463-470.
46. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillo-sis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360. (Pubitemid 351265310)
47. Angeli P, Merkel C Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008; 48(Suppl. 1): S93-103.
48. Cannon JP, Garey KW, Danziger LH. A prospective and ret-rospective analysis of the nephrotoxicity and eff cacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001; 21: 1107-1114. (Pubitemid 32807871)
49. Betts R, Glasmacher A, Maertens J, et al. Effcacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutro-penic patients. Cancer 2006; 106: 466-473. (Pubitemid 43100459)
50. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123: 877-884.